Antibacterial Research and Development

Antibacterial Research and Development

According to the Centers for Disease Control and Prevention, antibiotic-resistant infections are associated with an additional 23,000 deaths and 2 million illnesses in the United States each year. The estimated annual impact of antibiotic-resistant infections on the national economy is $20 billion in excess direct health care costs, and as much as $35 billion in lost productivity from hospitalizations and sick days. By holding the Re-Entering Antibacterial Drug Development Summit, we at Cambridge Healthtech Institute are trying to contribute to the efforts to revive antibacterial pipeline, and to improve antimicrobial stewardship in the United States and worldwide. This Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders, who are shaping the current state of antibacterial discovery and development.


Novel Monoclonal Antibodies for the Prevention and Treatment of Bacterial Infections.

Steven J. Projan. Ph.D., Senior Vice President, R&D, Innovative Medicines Unit, Head, Infectious Diseases & Vaccines, Medimmune

Disrupting Pseudomonas Biofilms? There’s a mAb for That

Antonio DiGiandomenica, Ph.D., Scientist II, Infectious Diseases, MedImmune.


New Antibiotics from Natural Products

Kim Lewis, Ph.D., University Distinguished Professor, Director, Antimicrobial Discovery Center, Department of Biology, Northeastern University

Re-entering The Antibacterial Space For The Microbiota Opportunity—Worth The Investment And Effort?

David W. Martin, M.D., CEO, AvidBiotics


Antibiotic Adjuvants to Reclaim Legacy Drugs

Gerard D. Wright, Ph.D., Director, Michael DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Canada Research Chair in Molecular Studies of Antibiotics.

Teaching Old Antibiotics New Tricks: A Combination Approach to Anti-Infective Therapy

Troy Lister, Ph.D., Head, Chemistry, Spero Therapeutics


Bringing the Full Power of Chemical Synthesis to Bear on the Discovery of New Antibiotics

Andrew G. Myers. Ph.D., Amory Houghton Professor of Chemistry, Department of Chemistry & Chemical Biology, Harvard University

Gram-Negative Antibiotics: The Importance of Compound Properties for Drug Discovery

Heinz E. Moser, Ph.D., Executive Director, Chemistry Infectious Diseases, Global Discovery Chemistry, Novartis Institutes for BioMedical Research


Trench Warfare: The Battle to Push Back the Lines of Gram-Negative Resistance

Todd A. Black, Ph.D., Director, Infectious Diseases, Merck

Understanding Drug Resistance of Gram-negatives: Contributions of Basic Science to Drug Discovery Efforts

Herbert P. Schweizer, Ph.D., Preeminence Professor of Microbiology, Department of Molecular Genetics and Microbiology, College of Medicine, Emerging Pathogens Institute, Institute for Therapeutic Innovation, University of Florida

Mechanism of Action

Bacterial cytological profiling, a tool for antibacterial drug discovery and susceptibility testing

Kit Pogliano, Ph.D., Professor, Division of Biological Sciences, University of California, San Diego

Context Specific Action Of Antibiotics Targeting The Ribosomal Peptidyl Transferase Center

Alexander Mankin, Ph.D., Professor, Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry & Pharmacognosy, University of Illinois at Chicago

Track 1 | Track 2 | Track 3 

For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5496

For exhibit & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-5412, Fax: (781) 972-5470

By Series:
By Region:

& Course Catalog

CHI Catalog 

Short Course DVDs